In a double-blind trial from Japan in 158 patients with rheumatoid arthritis comparing two nonsteroidal, anti-inflammatory drugs (NSAIDs), tolfenamic acid and indomethacin, 857 significance tests were reported.1 There were analyses of baseline data, multiple benefits and harms outcomes, subgroup analyses based on patient characteristics, control visits, etc. World record in number of P-values